Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
View Patent ↗Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
1. A method of providing progestin-only contraception to a woman while minimizing adverse side effects associated with the progestin-only contraception, comprising the steps of:
1) applying a transdermal patch to the outer skin surface of a woman and allowing the patch to remain applied to the outer skin surface of the woman for at least seven days; and
2) removing the transdermal patch from the outer skin surface after about seven days wherein the transdermal patch comprises norethindrone and/or norethindrone acetate as the only active hormonal agents in an amount of from about 1% w/w to about 15% w/w of the transdermal formulation and a permeation enhancer comprising isopropyl myristate and lauryl alcohol in an amount from about 3% w/w to about 15% w/w of the transdermal patch; and
the norethindrone and/or norethindrone acetate are administered from the transdermal patch at a rate and amount that provides a minimum norethindrone serum level of at least 300 pg/ml from about 24 hours to about 168 hours following application of the patch to the outer skin surface and a maximum norethindrone serum level of less than 1200 pg/ml about 24 to 96 hours following application of the patch to the outer skin surface.
2. The method described in claim 1 wherein the application step and removal step are conducted once a week for 4 to 12 weeks.
3. The method described in claim 2 wherein the application step and removal step are conducted once a week for 4 weeks.
4. The method described in claim 2 wherein the application step and removal step are conducted once a week for 12 weeks.
5. The method described in claim 1 wherein at least 0.35 mg/day of norethindrone and/or norethindrone acetate is delivered from the patch.
6. The method as described in claim 1 wherein the minimum norethindrone serum level is at least 350 pg/ml and is sustained from about 24 hours to about 168 hours following application of the patch to the outer skin surface.
7. The method as described in claim 1 wherein the maximum norethindrone serum level is less than 1100 pg/ml and is obtained about 24 to 96 hours following application of the patch to the outer skin surface.
8. The method of claim 1 , wherein the norethindrone and/or norethindrone acetate is present in an amount of from about 2.5% w/w to about 12% w/w of the transdermal formulation.
9. A method of providing progestin-only contraception to a woman while minimizing adverse side effects associated with the progestin-only contraception, comprising the steps of:
1) applying a transdermal patch to the outer skin surface of a woman and allowing the patch to remain applied to the outer skin surface of the woman for at least seven days;
2) removing the transdermal patch from the outer skin surface after about seven days wherein the transdermal patch comprises norethindrone acetate as the only active hormonal agent in an amount of from about 1% w/w to about 15% w/w of the transdermal formulation and a permeation enhancer comprising isopropyl myristate and lauryl alcohol in an amount from about 3% w/w to about 15% w/w of the transdermal patch; and
the norethindrone acetate is delivered from the patch at a rate and amount that provides a minimum norethindrone serum level of at least 300 pg/ml from about 24 hours to about 168 hours following application of the patch to the outer skin surface and a maximum norethindrone serum level of less than 1200 pg/ml about 24 to 96 hours following application of the patch to the outer skin surface.
10. The method described in claim 9 wherein the application step and removal step are conducted once a week for 4 to 12 weeks.
11. The method described in claim 10 wherein the application step and removal step are conducted once a week for 4 weeks.
12. The method described in claim 10 wherein the application step and removal step are conducted once a week for 12 weeks.
13. The method described in claim 9 wherein at least 0.35 mg/day of norethindrone acetate is delivered from the patch.
14. The method as described in claim 9 wherein the minimum norethindrone serum level is at least 350 pg/ml and is sustained from about 24 hours to about 168 hours following application of the patch to the outer skin surface.
15. The method as described in claim 9 wherein the maximum norethindrone serum level is less than 1100 pg/ml and is obtained about 24 to 96 hours following application of the patch to the outer skin surface.
16. The method of claim 9 , wherein the norethindrone acetate is present in an amount of from about 2.5% w/w to about 12% w/w of the transdermal formulation.
17. The method of claim 1 , wherein the adverse side effect is selected from the group consisting of strokes, myocardial infarctions, embolisms, breakthrough bleeding, and combinations thereof.
18. The method of claim 9 , wherein the adverse side effect is selected from the group consisting of strokes, myocardial infarctions, embolisms, breakthrough bleeding, and combinations thereof.